BrainCool AB (SE:BRAIN)
:BRAIN
Top Page
BrainCool AB
(BRAIN)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr0.52
▼(-9.66% Downside)
Action:ReiteratedDate:03/26/26
The score is primarily held back by weak financial performance—continued losses, negative gross profit in 2025, and ongoing cash burn—despite a debt-free balance sheet. Technical indicators are mixed and only mildly supportive, while valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Debt-free balance sheet
Zero reported debt and rising equity provide durable financial flexibility: lowers fixed financing costs, preserves borrowing optionality, and supports continued R&D and market rollouts. This capital structure reduces solvency risk while the company addresses commercialization and profitability gaps.
Negative Factors
Persistent operating losses
Consistent operating losses and a negative 2025 gross profit imply core product economics are not covering direct costs. This undermines sustainable profitability, limits reinvestment capacity, and means scaling revenue alone may not produce durable earnings without cost or pricing fixes.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt and rising equity provide durable financial flexibility: lowers fixed financing costs, preserves borrowing optionality, and supports continued R&D and market rollouts. This capital structure reduces solvency risk while the company addresses commercialization and profitability gaps.
Read all positive factors
BrainCool AB (BRAIN) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr216.79M
Dividend YieldN/A
Average Volume (3M)201.46K
Price to Earnings (P/E)―
Beta (1Y)0.19
Revenue Growth16.38%
EPS Growth35.71%
CountrySE
Employees20
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.00
Shares Outstanding394,878,140
10 Day Avg. Volume223,544
30 Day Avg. Volume201,464
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)0.85
Price to Sales (P/S)4.14
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)kr73.00M
BrainCool AB Business Overview & Revenue Model
Company Description
BrainCool AB (publ), a medical device company, together with its subsidiaries, engages in the development, marketing, and sale of medical cooling systems for the healthcare sector in Sweden. The company offers products for medical cooling treatmen...
How the Company Makes Money
null...
BrainCool AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 36.21M | 39.96M | 23.23M | 17.59M | 9.26M |
| Gross Profit | -40.88M | 13.13M | 12.12M | -46.16M | -48.93M |
| EBITDA | -29.99M | -34.06M | -49.86M | -35.07M | -32.16M |
| Net Income | -37.05M | -44.04M | -61.28M | -45.61M | -38.75M |
Balance Sheet | |||||
| Total Assets | 192.38M | 162.04M | 133.28M | 133.67M | 99.35M |
| Cash, Cash Equivalents and Short-Term Investments | 39.57M | 31.40M | 25.06M | 41.21M | 13.58M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 35.00M |
| Total Liabilities | 16.58M | 16.11M | 21.54M | 17.44M | 54.12M |
| Stockholders Equity | 175.80M | 145.93M | 111.74M | 116.23M | 45.23M |
Cash Flow | |||||
| Free Cash Flow | -56.49M | -70.20M | -67.23M | -53.67M | -35.06M |
| Operating Cash Flow | -52.68M | -62.64M | -61.16M | -46.27M | -24.25M |
| Investing Cash Flow | -6.54M | -7.57M | -6.17M | -7.59M | -10.82M |
| Financing Cash Flow | 67.33M | 76.80M | 50.93M | 81.28M | 36.39M |
BrainCool AB Technical Analysis
Negative
0.58
Price Trends
0.53
Positive
0.54
Positive
0.82
Negative
Market Momentum
0.01
Positive
47.80
Neutral
75.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BRAIN, the sentiment is Negative. The current price of 0.58 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.53, and below the 200-day MA of 0.82, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 47.80 is Neutral, neither overbought nor oversold. The STOCH value of 75.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BRAIN.
BrainCool AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr375.48M | -11.61 | -27.25% | ― | -0.02% | -85.98% | |
55 Neutral | kr877.94M | 168.74 | 6.93% | ― | -5.80% | -65.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr310.04M | -6.28 | -104.38% | ― | 21.88% | 48.86% | |
46 Neutral | kr216.79M | -4.05 | -27.22% | ― | 16.38% | 35.71% | |
46 Neutral | kr571.22M | -88.91 | -2.52% | ― | -8.10% | 62.08% | |
44 Neutral | kr861.25M | -17.24 | -4.42% | ― | 13.48% | 28.98% |
* Healthcare Sector Average
SE:BRAIN
BrainCool AB
0.55
-1.03
-65.28%
SE:BACTI.B
Bactiguard Holding AB
16.30
-15.00
-47.92%
SE:CRAD.B
C-Rad AB Class B
26.00
-0.70
-2.62%
SE:ACARIX
Acarix AB
0.28
0.06
24.89%
SE:SEDANA
Sedana Medical AB
8.67
1.15
15.29%
SE:MNTC
Mentice AB
13.35
-4.45
-24.98%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.